Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial

Barinthus Biotherapeutics plc.

2024-Q1 EPS reported -$0.40

Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).
Cash, cash equivalents and restricted cash of $130.0M as of March 31, 2024; cash runway into Q4 2025.
R&D expenses $11.1M (up from $9.8M), G&A $6.0M (down from $12.1M).
FDA IND clearance received for VTP-1000 Phase 1 trial in celiac disease; first patient dosing expected Q3 2024.
Appointed Dr. Leon Hooftman as CMO, effective June 3, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Barinthus Biotherapeutics plc. reported financial results for first quarter of 2024.

Period: first quarter of 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Barinthus Biotherapeutics plc (the “Company”) announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-24-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.